Navigation Links
Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
Date:1/31/2008

in Ann Arbor, Michigan, and the Mayo Clinic in Rochester, Minnesota.

The trial (REO 014) is a Phase II, open-label, single agent study whose primary objective is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity of intravenous, multiple dose REOLYSIN(R) in patients with bone and soft tissue sarcomas metastatic to the lung. REOLYSIN(R) is delivered intravenously to patients at a dose of 3x10(10) TCID(50) for five consecutive days. Patients may receive additional five-day cycles of therapy every four weeks for a maximum of eight cycles. Up to 52 patients will be enrolled in the study.

Eligible patients must have a bone or soft tissue sarcoma metastatic to the lung deemed by their physician to be unresponsive to or untreatable by standard therapies. These include patients with osteosarcoma, Ewing sarcoma family tumours, malignant fibrous histiocytoma, synovial sarcoma, fibrosarcoma and leiomyosarcoma.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the

meaning of Section 21E of the Securities Exchange Act of 1934, as

amended. Forward-looking statements, including the Company's expectations

related to the U.S. Phase II sarcoma clinical trial and the Company's

belief as to the potential of REOLYSIN(R) as a cancer therapeutic,

involve known and unknown risks and uncertainties, which could cause the

Company's ac
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
2. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
3. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
4. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
5. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
6. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
7. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
10. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
11. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... San Bruno, CA (PRWEB) March 26, 2015 ... organization (CRO), announced today several management and executive ... role of Chief Financial Officer (CFO) and member of ... Vice President of Business Operations, and Sue Dowden will ... Tony Taricco, co-founder and current Chief Operations Officer (COO), ...
(Date:3/26/2015)... Massachusetts and CINCINNATI ... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... a three-year, broad research collaboration for rare diseases. The ... develop novel therapies to treat rare diseases with ... commercialization capabilities with Cincinnati Children,s research expertise. As ...
(Date:3/26/2015)... "In America," the popular news television program that ... hosted by legendary film actor James Earl Jones, has announced ... upcoming segment. , Botany is commonly described as the ... quite a bit more complicated than that. Scientists and other ... organisms, from the smallest bacteria known to man to the ...
(Date:3/25/2015)... Agnition announced today that it will ... airing for the first time at 7:30 a.m. CST ... will explore the extremely important role soil microbes perform ... patented Microbial Catalystâ„¢ technology that enhances soil and plant ... will air again on April 28. , A biochemist ...
Breaking Biology Technology:PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2
... Wisconsin attracts far fewer defense research dollars annually than ... public and private initiatives are quietly positioning the state ... ,These projects and others like them could thrive as ... to the unique threats it poses. Tom Still, president ...
... - When scientists look back at this early period ... the hype surrounding this controversial research, but they won't ... cells from embryos of contributing to it. , ,Outlining ... University of Wisconsin-Madison professor James Thomson took ...
... - Wisconsin's role in tackling the world's most worrisome ... 2006 annual conference of the Wisconsin Biotechnology and Medical ... Oct. 12 at the GE Healthcare Institute in ... Doyle and former Gov. Tommy Thompson, but session topics ...
Cached Biology Technology:Chippewa Valley firms land more defense work 2Chippewa Valley firms land more defense work 3Chippewa Valley firms land more defense work 4Chippewa Valley firms land more defense work 5Chippewa Valley firms land more defense work 6Chippewa Valley firms land more defense work 7Thomson lends perspective to stem cell expectations 2Thomson lends perspective to stem cell expectations 3Wisconsin's role in health a focus of biotech event 2Wisconsin's role in health a focus of biotech event 3
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/23/2015)... , March 23, 2015 SoundView Technology Group ... NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView was one ... feedback on their experience with the Wocket in multiple scenarios ... CVS, Whole Foods and other retailers, making both debit and ... Tuttle also says, "If the company meets their plans ...
(Date:3/20/2015)... 2015 Research and Markets ( ... "India Sensors Market Forecast and Opportunities 2020" ... sensor market is projected to grow at a ... electronics, automotive, industrial and healthcare sectors are the ... In addition, adoption of MEMS technology in sensors ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... ON - In a new study from Lawson Health ... genetic pathway influencing the spread of cancer cells. The ... for treatment. Regular cell division is regulated by ... to ensure cells divide at a healthy, balanced rate. ...
... 3, 2012) A new book produced by the ... how well-managed protected areas with good law enforcement have ... of insecurity and war. , The book documents how ... on the planet, faces a variety of challenges from ...
... and improve lung-cancer screening by combining a blood test with ... trial combines a CT chest scan and the EarlyCDT-Lung blood ... recent research demonstrating that CT screening alone can reduce lung-cancer ... high-risk patients can reduce lung-cancer deaths. But we need to ...
Cached Biology News:Africa's Rift Valley saved by parks 2Trial seeks improved lung-cancer screening by combining imaging and biomarkers 2
... Time- and temperature-controlled microwave oven ... and Antigen Retrieval of formalin-fixed, ... ease of use, high throughput ... high performance. When used in ...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
...
Biology Products: